H5N1 Testing Program Coming from CAP This Fall
While the current risk to humans of H5N1 remains low, CAP is launching a testing program to help labs better detect and subtype the virus.
While the current risk to humans of H5N1 remains low, CAP is launching a testing program to help labs better detect and subtype the virus.
Lipoprotein(a), or Lp(a), is a genetically determined and under-recognized cardiovascular disease risk factor.
Most Medicaid-enrolled children with autism or intellectual disability are not receiving recommended genetic testing.
A new survey finds that data overload remains a top challenge for labs, but is also an opportunity for AI-driven transformation.
Lucid Diagnostics and Hoag have launched a comprehensive esophageal precancer screening program using the non-endoscopic EsoGuard DNA test.